ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Dividends per Share : HK$0.00 (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Dividends per Share?

ImmuneOnco Biopharmaceuticals (Shanghai)'s dividends per share for the six months ended in Dec. 2023 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

ImmuneOnco Biopharmaceuticals (Shanghai) Dividends per Share Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Dividends per Share Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Dividends per Share

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	-	-	-	-	-

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividends per Share

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Yield % distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Yield % falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Dividends per Share Calculation

Dividends paid to per common share.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.615
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

ImmuneOnco Biopharmaceuticals (Shanghai) Dividends per Share Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines